Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML

NCT03384212 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT03384212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03384212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 3
Overall status
Unknown status
Start date
August 1, 2016
Completion date
July 31, 2022
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoeitic stem cell transplantation, high risk acute myeloid leukemia